Telesis Bio

Telesis Bio FCF Growth

The Year-over-Year Free Cash Flow Growth of Telesis Bio (TBIO) as of Oct 30, 2026 is 15.14 %. In the previous year, Year-over-Year Free Cash Flow Growth was -12.01 % — a change of -226.00% (higher).

FCF Growth

15.14 %

YoY

-226.00%

Last updated:

Year-over-Year Free Cash Flow Growth of Telesis Bio is 2023 15.14 % . Year-over-Year Free Cash Flow Growth of Telesis Bio was 2022 -12.01 % . It decreases by -226.00% higher compared to the previous year.

The Telesis Bio FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2017
-117.89 USD
Jan 1, 2018
46.39 USD
Jan 1, 2019
77.47 USD
Jan 1, 2020
-140.92 USD
Jan 1, 2021
-147.37 USD
Jan 1, 2022
-12.01 USD
Jan 1, 2023
15.14 USD
The Telesis Bio FCF Growth history
YEARFCF GrowthYoY
15.14 %-226.00%
-12.01 %-91.85%
-147.37 %+4.58%
-140.92 %-281.90%
77.47 %+67.00%
46.39 %-139.35%
-117.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telesis Bio Stock analysis

What does Telesis Bio do? Codex DNA, Inc. develops genomic tools for biomedical and industrial applications, focusing on synthetic biology solutions to overcome bottlenecks in DNA and mRNA production. Its BioXp systems, including the BioXp 3250, serve as end-to-end automated workstations, while BioXp kits generate synthetic DNA and mRNA. The company offers 14 SARS-CoV-2 full-length genomes, RNA controls, and Vmax X2 cells as part of its product portfolio. BioXp systems are placed globally with approximately 200 units deployed. The firm targets researchers and biotech companies needing scalable DNA and mRNA synthesis, leveraging its automated workflow solutions. Products like BioXp kits and benchtop reagents complement the core systems, addressing limitations in current solutions. The company has launched eight BioXp kits and three benchtop reagent kits, supporting applications across biomedical and industrial sectors. Revenue streams come from selling BioXp systems, kits, and reagents directly to research institutions and biotechnology firms. The BioXp 3250 system, BioXp kits, and benchtop reagent kits are key products driving sales. Vmax X2 cells and SARS-CoV-2 related products also contribute to the company's revenue. Global deployment of 200 BioXp systems indicates strong market adoption among customers in the synthetic biology space. Telesis Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telesis Bio stock

Year-over-Year Free Cash Flow Growth of Telesis Bio is 15.14 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Telesis Bio since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Telesis Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Telesis Bio

All Key Metrics — Telesis Bio